Sabrina Serani

The subcutaneous version of the cancer treatment atezolizumab is approved in all adult intravenous indications, including in lung, liver, and skin cancers.

The phase 3 Shorespan-007 trial will compare bomedemstat with hydroxyurea in patients with treatment-naive essential thrombocythemia.

Tebapivat, a novel pyruvate kinase activator, is being investigated for the treatment of anemia in patients with lower-risk myelodysplastic syndromes.

The investigational agent certepetide has been granted FDA orphan drug designation for the treatment of patients with cholangiocarcinoma.

The trial previously met its primary end point of progression-free survival, and the final overall survival analysis was recently presented at the 2024 World Conference on Lung Cancer.

The next-generation radiopharmaceutical ABD-147 was previously granted FDA fast track designation in extensive-stage small cell lung cancer.

The bispecific T-cell engager tarlatamab showed continued efficacy and tolerable safety, according to follow-up from the phase 2 DeLLphi-301 study.

The novel agent VMT01 is designed to target and deliver 212Pb to MC1R-expressing tumors like metastatic melanoma.

Ifinatamab deruxtecan, a novel antibody-drug conjugate, returned promising response rates at both dose levels evaluated among patients with small cell lung cancer.

IBI363 has earned fast track designation from the FDA for the treatment of previously treated unresectable advanced melanoma.

The ready-to-use formulation of bortezomib is now an FDA-approved option for patients with multiple myeloma and mantle cell lymphoma.

The FDA has approved FoundationOne CDx and FoundationOne Liquid CDx as companion diagnostics to be used with olaparib, abiraterone, and prednisone or prednisolone BRCA-mutated metastatic castration-resistant prostate cancer.

Findings from the CUPISCO study found that molecularly guided therapy is more effective than standard chemotherapy for patients with unfavorable nonsquamous cancer of unknown primary.

This designation follows the fast track designation that was granted to OBX-115 for the same indication in July 2024.

The phase 3 KEYNOTE-867 and KEYNOTE-630 studies will be stopped due to futility, following analysis from independent data monitoring committees.

The phase 3 study will investigate fezolinetant for vasomotor symptoms in patients receiving adjuvant endocrine therapy.

Christopher Moertel, MD, discussed findings from the phase 2 ReNeu trial of mirdametinib in adult and pediatric patients with neurofibromatosis type 1-associated plexiform neurofibromas.

Data from the phase 2 ReNeu study presented at the 2024 ASCO Annual Meeting support this priority review designation.

The innovative bispecific antibody INV724 targets GD2 and B7-H3 with high specificity for neuroblastoma.

The FDA’s Oncologic Drug Advisory Committee will meet on September 26, 2024, to discuss PD-L1 cutoffs for immune checkpoint inhibitors in gastric, gastroesophageal, and esophageal cancers.

BGB-16673 has been granted FDA fast track designation based on findings from a phase 1/2 study of the oral agent in relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

CAR T-cell therapy is a game-changing treatment, but it is not without the potential for serious adverse effects. Researchers and physicians still wonder about the incidence and prevalence of these risks.

Christina Henson, MD, discussed proposed guidelines for head and neck cancer imaging to improve patient outcomes and consistency across practices.

With this designation, the sponsor of APG-157 is eligible for more frequent interaction with the FDA, facilitating faster drug development and review for this neoadjuvant head and neck cancer therapy.

An independent data monitoring committee assessed that the PRECISION1 trial of nab-sirolimus in solid tumors would not meet an efficacy threshold to support the agent’s accelerated approval.

Biagio Ricciuti, MD, discussed findings from a retrospective study exploring the use of immune checkpoint inhibitors for longer than 2 years in patients with non–small cell lung cancer.

The application is supported by the phase 3 CheckMate -9DW study, and the FDA has set a target action date of April 21, 2025.

Byoung Chul Cho, MD, PhD, discussed findings from cohort C of the CHYRSALIS-2 study exploring amivantamab plus lazertinib in patients with non–small cell lung cancer with uncommon EGFR mutations.

Lazertinib and amivantamab as a first-line treatment for patients with locally advanced or metastatic non–small cell lung cancer with specific EGFR mutations demonstrated superior efficacy compared with standard treatment.

The breakthrough therapy designation is supported by findings from the phase 3 DESTINY-Breast06 study comparing the antibody-drug conjugate with chemotherapy in patients with HR+/HER2-low breast cancer.